Novartis has made an offer to buy its manufacturing partner CELLforCURE. If accepted, Novartis will add a facility in Les Ulis, France to its CAR-T network. Novartis announced it was working with CELLforCURE in July, transferring its chimeric antigen receptor (CAR) T-cell production technology to the French contract development and manufacturing organization (CDMO) from its site in Morris Plain, New Jersey. Less than six months on, the Swiss pharma giant has made an offer to buy “the share capital of…